The White House announced an agreement with pharmaceutical manufacturers to increase access to GLP-1 antagonist medications for the treatment of obesity and diabetes. Qualifying Medicare and Medicaid patients can receive certain GLP-1 drugs at a significant discount. Furthermore, individuals who purchase these drugs through TrumpRx, the White House's new direct-to-consumer will also receive discounts for cash purchases. Medicare prices of Ozempic (semaglutide), Wegovy (semaglutide), Mounjaro (tirzepatide), and Zepbound (tirzepatide) will be $245. State Medicaid programs will have access to these prices, and Medicare patient co-pays for these drugs will be capped at $50 a month. When purchased through TrumpRx, the monthly price of Ozempic and Wegovy will be $350, while the monthly price of Zepbound and Orforglipron (a new GLP-1 medication still under review byt the FDA) will be $346. In the event that the FDA later approves an oral formulation of Wegovy , or certain similar GLP-1 drugs in each company’s pipeline intended to be taken orally rather than as an injection, the initial dose of those drugs will be priced at $150 per month The announced prices are expected to go into effect in January of 2026 for cash payers through TrumpRx, mid-2026 for Medicare patients, and on an ongoing basis for Medicaid enrollees, depending on when states register.
